Alloy Therapeutics is a biotech company that makes medicine by democratizing access to foundational drug discovery platforms and services.
Alloy Therapeutics makes medicine by democratizing access to foundational drug discovery platforms and services. Alloy-Gx, its first platform, is a royalty-free suite of immunocompetent transgenic mice enabling best-in-class in vivo human antibody discovery. Founded in 2017, Alloy Therapeutics is headquartered in Waltham, Massachusetts.
Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
---|---|---|---|---|---|---|
Oct 3, 2022 | Series D | $42M | 5 | 8VC Mubadala Capital Ventures | — | Detail |
Apr 2, 2021 | Series C | $75M | 10 | 8VC Peter Thiel Presight Capital | — | Detail |
Jun 5, 2020 | Series B | $11.25M | 2 | 8VC | — | Detail |
Date
Company Name
|
Round | Money Raised | Industry | Lead Investor |
---|---|---|---|---|
Jun 2, 2022
Vernal Biosciences
|
Series Unknown | $21M | Biotechnology | — |
Apr 6, 2022
Tegmine Therapeutics
|
Corporate Round | — | Biotechnology | Yes |
Mar 8, 2022
Mytide Therapeutics
|
Series A | $7M | Biotechnology | Yes |
Jan 4, 2022
Wheeler Bio
|
Seed | $14M | Biotechnology | Yes |
Jul 21, 2021
Wheeler Bio
|
Funding Round | — | Biotechnology | Yes |
Investor Name | Lead Investor | Funding Round |
---|---|---|
8VC | Yes | Series D |
Mubadala Capital Ventures | Yes | Series D |
Peter Thiel | Yes | Series C |
Founders Fund | — | Series D |
Presight Capital | — | Series D |
Thiel Capital | — | Series D |
Gaingels | — | Series C |
Alexandria Venture Investments | — | Series C |
Bossanova Investimentos | — | Series C |
Luma Bio-IT | — | Series C |
Alloy Therapeutics has acquired 1 organizations. Their most recent acquisition was deepCDR Biologics on Dec 9, 2021. They acquired deepCDR Biologics for 0.
Date
Company Name
|
Industry | Acquisition Type | Price | |
---|---|---|---|---|
Dec 9, 2021
deepCDR Biologics
|
Biotechnology | acquisition | — | Detail |